Department of Organ Transplant and Regenerative Surgery, Kyoto Prefectural University of Medicine, Graduate School of Medical Science, 465 Hirokoji Kawaramachi, Kamigyo-ku, Kyoto, 602-0841, Japan.
Surg Today. 2010 Jun;40(6):514-25. doi: 10.1007/s00595-009-4214-3. Epub 2010 May 23.
Recent advances in immunosuppressant therapy have dramatically reduced the frequency of acute rejection of organ transplants. Subsequently, the short-term graft survival rate has been improved, and ABO blood type-incompatible and existing anti-HLA antibody-positive kidney transplantation has been enabled, which has increased the availability of living kidney donors. Japan has a unique history and strategies of liver transplantation (LT) for various liver diseases. The outcomes of living donor liver transplantation (LDLT) in Japan is comparable to that of deceased donor liver transplantation (DDLT) in Western countries despite the relatively short history of LT. The main disadvantage of LT in Japan is donor shortage mainly due to the small number of available deceased donors. There are some disadvantages with LDLT in autoimmune liver diseases because of the dependence on blood relative donors. The first brain-dead pancreas transplantation (PTx) was performed in 2000. Since that time, 42 brain-dead PTx, 2 non-heart beating PTx, and 14 living donor PTx had been performed by the end of 2007. One of the 44 recipients of deceased donor PTx died of unknown causes 11 months after transplantation. Although most of the deceased donors in Japan were marginal and their condition was not favorable, the results of these cases were comparable to those of Western countries. Fourteen intestinal transplantations (ITx) had been performed by the end of 2007 in four transplant centers. There were 3 deceased donor and 11 live donor transplants. The original diseases included short bowel syndrome (n = 6), intestinal function disorder (n = 6), and retransplantation (n = 2). The graft and patient survival rate are 60% and 69%, respectively. Eight recipients survived and stopped parenteral nutrition with full-functioning grafts. Amendment of the Japanese law for the utilization of deceased donors should increase the number available donors in the future.
近年来,免疫抑制剂治疗的进展显著降低了器官移植的急性排斥反应频率。因此,短期移植物存活率得到了提高,并且实现了 ABO 血型不相容和存在抗 HLA 抗体的肾移植,这增加了活体供肾者的可用性。日本在各种肝脏疾病的肝移植(LT)方面具有独特的历史和策略。尽管 LT 的历史相对较短,但日本活体供者肝移植(LDLT)的结果与西方国家的死体供者肝移植(DDLT)相当。日本 LT 的主要缺点是供体短缺,主要是由于可利用的死体供者数量较少。在自身免疫性肝病中,由于依赖血缘关系供者,LDLT 存在一些缺点。首例脑死亡胰腺移植(PTx)于 2000 年进行。自那时以来,截至 2007 年底,已进行了 42 例脑死亡 PTx、2 例非心脏死亡 PTx 和 14 例活体供者 PTx。44 例接受死体供者 PTx 的患者中,有 1 例在移植后 11 个月死于不明原因。尽管日本的大多数死者供者都处于边缘状态,情况不佳,但这些病例的结果与西方国家相当。截至 2007 年底,四个移植中心共进行了 14 例肠移植(ITx)。其中有 3 例死体供者和 11 例活体供者。原发疾病包括短肠综合征(n = 6)、肠功能障碍(n = 6)和再移植(n = 2)。移植物和患者的存活率分别为 60%和 69%。8 例受者存活并停用了具有完整功能的移植物的肠外营养。日本关于死者供者利用的法律修正案应该会在未来增加可利用供者的数量。